Kestra Medical Technologies, Ltd.
Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) is a wearable medical device and digital healthcare company focused on cardiac monitoring and protection. Its core product, the ASSURE Wearable Cardioverter Defibrillator (WCD), continuously monitors heart rhythms and delivers a defibrillation shock when it detects… From the company’s description.
In fiscal 2025, Kestra Medical Technologies, Ltd. reported revenue of $95.13M, up 59.0% from fiscal 2024, and a net loss of $131.61M. Its operating margin was −141.6%, and operations used $81.70M in cash. Over the twelve months to Jul 31, 2026, revenue was $106.73M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Kestra Medical Technologies, Ltd. does
In the company’s own words
Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) is a wearable medical device and digital healthcare company focused on cardiac monitoring and protection. Its core product, the ASSURE Wearable Cardioverter Defibrillator (WCD), continuously monitors heart rhythms and delivers a defibrillation shock when it detects life-threatening arrhythmias. The broader Cardiac Recovery System platform combines the device with the ASSURE patient application, Kestra CareStation remote patient management, Heart Alert Services and ASSURE Assist, supporting patient engagement, clinical workflows and emergency response. Kestra leases the WCD to patients at elevated risk of sudden cardiac arrest, with healthcare providers prescribing it and third-party payors—including Medicare, Medicaid and private insurers—generally paying for the service. The company primarily sells through a U.S. direct sales force targeting cardiologists, hospitals and clinics. It operates as a single cardiac recovery platform business; nearly all revenue comes from leasing the ASSURE WCD and related services. In fiscal 2026, nearly 40,000 patients had received protection from the device since its commercial launch. Kestra completed its initial public offering in March 2025. Its website is www.kestramedical.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- KIRKLAND, WA
- Fiscal year end
- April
- CIK
- 1877184
- SIC
- 3841
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Kestra Medical Technologies, Ltd. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Kestra Medical Technologies, Ltd.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Kestra Medical Technologies, Ltd. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Kestra Medical Technologies, Ltd.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Kestra Medical Technologies, Ltd.'s last four quarterly filings that the numbers alone won't show?”